{"entity":{"id":"rezatapopt","kind":"drug","name":"Rezatapopt","aka":["PC14586"],"tldr":"Rezatapopt is an experimental pill from PMV Pharma, in phase 2 trials for solid tumours with the TP53 Y220C mutation.","summary":"Rezatapopt (PC14586) is a small molecule, oral from PMV Pharma. Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor. It is being developed for any tumour type with the TP53 Y220C mutation, in the phase 2 part of the PYNNACLE study (NCT04585750); a study in myelodysplastic syndrome and acute myeloid leukaemia (NCT06616636) and a drug-interaction study (NCT07372625) are also recruiting. The company reports an FDA Fast Track designation.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"PMV Pharma pipeline","url":"https://www.pmvpharma.com/pipeline/"},{"label":"ClinicalTrials.gov NCT04585750","url":"https://clinicaltrials.gov/study/NCT04585750"},{"label":"ClinicalTrials.gov NCT07372625","url":"https://clinicaltrials.gov/study/NCT07372625"},{"label":"ClinicalTrials.gov NCT06616636","url":"https://clinicaltrials.gov/study/NCT06616636"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["tp53"],"drugs":[],"companies":["pmv-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04585750","nct07372625","nct06616636"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"PC14586","modality":"Small molecule, oral","mechanism":"Binds the p53 protein made from the TP53 Y220C mutation, stabilising it so that it can work again as a tumour suppressor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rezatapopt/","neighbours":{"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"company":[{"id":"pmv-pharma","kind":"company","name":"PMV Pharma","route":"/companies/pmv-pharma/"}],"trial":[{"id":"nct06616636","kind":"trial","name":"A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)","route":"/trials/nct06616636/"},{"id":"nct07372625","kind":"trial","name":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","route":"/trials/nct07372625/"},{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","route":"/trials/nct04585750/"}]}}